Potential clinical applications of halichondrins in breast cancer and other neoplasms

References

• KuznetsovGTowleMJChengHInduction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389Cancer Res2004645760576615313917
   PubMed Web of Science ®Google Scholar
• MasudaAMaenoKNakagawaTAssociation between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancersAm J Pathol200316331109111612937152
   PubMed Web of Science ®Google Scholar
• WangTHWangHSSoonYKPaclitaxel-induced cell death: where the cell cycle and apoptosis come togetherCancer200088112619262810861441
   PubMed Web of Science ®Google Scholar
• UemuraDTakahashiKYamamotoTNorhalichondrin A: an antitumor polyether macrolide from a marine spongeJ Am Chem Soc198510747964798
   Web of Science ®Google Scholar
• HirataYUemuraDHalichondrins: antitumor polyether macrolides from amarine spongePure Appl Chem198658701710
   Web of Science ®Google Scholar
• TowleMJSalvatoKABudrowJIn vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BCancer Res2001611013102111221827
   PubMed Web of Science ®Google Scholar
• BaiRLPaullKDHeraldCLMalspeisLPettitGRHamelEHalichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity dataJ Biol Chem199126615882158891874739
   PubMed Web of Science ®Google Scholar
• BaiRLCichaczZAHeraldCLPettitGRHamelESpongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulinMol Pharmacol1993447577668232226
   PubMed Web of Science ®Google Scholar
• HamelENatural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin BPharmacol Ther19925531511287674
   PubMed Web of Science ®Google Scholar
• RaiSSWolffJLocalization of the Vinblastine-binding site on β-tubulinJ Biol Chem199627114707147118663038
   PubMed Web of Science ®Google Scholar
• ZhouJGiannakakouPTargeting microtubules for cancer chemotherapyCurr Med Chem Anticancer Agents20055657115720262
   PubMedGoogle Scholar
• JordanMAKamathKMannaTThe primary antimitotic mechanism of action of the synthetic halicondrin E7389 is suppression of microtubule growthMol Cancer Ther200541086109516020666
   PubMed Web of Science ®Google Scholar
• SeletskyBMWangYHawkinsLDStructurally simplified macrolactone analogues of halichondrin BBioorg Med Chem Lett2004145547555015482921
   PubMed Web of Science ®Google Scholar
• AldayPHCorreiaJJMacromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugationBiochemistry2009487927793819586046
   PubMed Web of Science ®Google Scholar
• AgoulnikSKuznetsovGTendykeKSensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin isotype expression in human breast cancer cell linesJ Clin Oncol20052316S abstr 2012
   Google Scholar
• StengelCNewmanSPLeeseMPPotterBVReedMJPurohitAClass III beta-tubulin expression and in vitro resistance to microtubule targeting agentsBr J Cancer201010231632420029418
   PubMed Web of Science ®Google Scholar
• Eisai IncProduct informationWoodcliffe Lake, NJ, USA
   Google Scholar
• SynoldTWMorganRJNewmanEMA Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. 2005 ASCO Annual Meeting ProceedingsJ Clin Oncol20052316S3036
   Web of Science ®Google Scholar
• SynoldTWLawrenceJXiBColevasADLewisMDDoroshowJHHuman pharmacokinetics of E7389 (Halichondrin B analog), a novel anti-microtubule agent undergoing phase I investigation in the California Cancer Consortium (CCC)Proc Am Soc Clin Oncol200322 abstr 575
   Google Scholar
• GoelSMitaACMitaMA Phase I study of Eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesClin Cancer Res2009154207421219509177
   PubMed Web of Science ®Google Scholar
• TanARRubinEHWaltonDCPhase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumorsClin Cancer Res2009154213421919509146
   PubMed Web of Science ®Google Scholar
• MinamiHMukoharaTNagaiSMukaiHNamikiMA Phase I study of eribulin mesylate (E7389) in patients with refractory cancersEur J Cancer20086140
   Web of Science ®Google Scholar
• WitteveenPMarchettiSMergui-RoelvinkMEribulin mesylate pharmacokinetics in patients with hepatic impairmentJ Clin Oncol20102815s abst 2582
   Google Scholar
• DevrieseLWandersJJennerAEribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazoleEORTC-NCI-AACR Symposium20108181 abst 574
   Google Scholar
• JansenMVernaz-GrisMDesJardinsCPopulation pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)J Clin Oncol20092715S abst 2524
   PubMedGoogle Scholar
• VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol2009272954296119349550
   PubMed Web of Science ®Google Scholar
• CortesJVahdatLBlumJLPhase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJ Clin Oncol2010283922392820679609
   PubMed Web of Science ®Google Scholar
• IwataHAogiKMasudaNEfficacy and safety of eribulin in Japanese patients with advanced breast cancerJ Clin Oncol201028 abst 1081
   Web of Science ®Google Scholar
• CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet201137791492321376385
   PubMed Web of Science ®Google Scholar
• Eisai IncE7389 versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanesClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)6132006 [last updated on August 2, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00337103 NLM identifier: NCT00337103
   Google Scholar
• SpiraAIIannottiNOSavinMAA Phase II study of eribulin mesylate E7389 in patients with advanced, previously treated non-small cell lung cancerClin Lung Cancer201113313821862415
   PubMed Web of Science ®Google Scholar
• GitlitzBJDaviesAMBelaniCPA Phase II study of the halichondrin B analog, E7389, in patients with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trialJ Clin Oncol20092715s abst 8056
   Google Scholar
• Eisai Inc PharmaBio Development IncEribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second line therapy in patients with stage IIIB or IV nonsquamous non-small cell lung cancerClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)5172010 [last updated on March 29, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01126736 NLM identifier: NCT01126736
   Google Scholar
• Eisai IncEribulin mesylate in combination with intermittent erlotinib in patients with previously treated, advanced non-small cell lung cancerClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)4122010 [last updated on December 8, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01104155 NLM identifier: NCT01104155
   Google Scholar
• Eisai IncA dose-finding study of E7389 in combination with carboplatin in patients with solid tumorsClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)12212005 [last updated on May 3, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00268905 NLM identifier: NCT00268905
   Google Scholar
• ArnoldSMMoonJWilliamsonSKPhase II evaluation of eribulin mesylate (E7389, NSC707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618Invest New Drugs20112935235919937365
   PubMed Web of Science ®Google Scholar
• de BonoJSMarotoPCalvoEPhase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapyASCO Genitourinary Cancer Symposium2009 abst 166
   Google Scholar
• SteinMNChenYHudesGRECOG 5805: a Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer (CRPC)J Clin Oncol20102815s abst 4556
   Google Scholar
• HensleyMLKravetzSJSimaCEribulin mesylate (halichondrin B analog E7389) in platinum-resistant epithelial ovarian cancer (PREOC): a CTEP-sponsored Phase II studyJ Clin Oncol20092715s abst 5561
   Google Scholar
• HensleyMLKravetzSJJiaXEribulin mesylate (halichondrin B analog E7389) in platinum-sensitivy ovarian cancer: a Phase II study, CTEP # 74J Clin Oncol201129 abst 5090
   Web of Science ®Google Scholar
• RenoufDJTangPAMajorPA Phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancerInvest New Drugs2011 In press
   PubMed Web of Science ®Google Scholar
• SchoffskiPRay-CoquardILCioffAActivity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052)J Clin Oncol20102815s abst 10031
   Google Scholar
• SynoldTWTsao-WeiDDQuinnDIPhase I and pharmacokinetic study of eribulin (E7389) in patients with renal dysfunction and advanced urothelial cancer (UC): a California Cancer Consortium TrialJ Clin Oncol20102815s abst 2527
   Google Scholar
• QuinnDIAparicioATsao-WeiDDPhase II study of eribulin (E7389) in patients with advanced urothelial cancer (UC) – final report: a California Cancer Consortium-led NCI/CTEP-sponsored trialJ Clin Oncol20102815s abst 4539
   Google Scholar
• Eisai IncEribulin with trastuzumab as first-line therapy for locally recurrent or metastatic HER2 positive breast cancerClinical Trialsgov [Internet]Bethesda, MDNational Library of Medicine (US)12312010 [last updated on March 30, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01269346 NLM identifier: NCT01269346
   Google Scholar
• Eisai IncDose dense doxorubicin and cyclophosphamide followed by eribulin mesylate for the adjuvant treatment of early stage breast cancerClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)3222011 [last updated on December 13, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01328249 NLM identifier: NCT01328249
   Google Scholar
• Northwestern University Eisai IncCarboplatin and eribulin mesylate in triple negative breast cancer patientsClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)612011 [last updated on June 10, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01372579 NLM identifier: NCT01372579
   Google Scholar
• Eisai IncA study of single-agent eribulin mesylate as first-line therapy for locally recurrent or metastatic Human epidermal growth factor receptor two (HER2) negative breast cancerClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)12282010 [last updated on April 28, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01268150 NLM identifier: NCT01268150
   Google Scholar
• Eisai Ltd Eisai IncA Phase 1b/2, multicenter, randomized, open-label, dose-escalation and confirmation study of eribulin in combination with capecitabineClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)3242011 [last updated on March 24, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01323530 NLM identifier: NCT01323530
   Google Scholar
• Eisai IncPhase 3 study to compare the efficacy and safety of eribulin with dacarbazine in subjects with soft tissue sarcomaClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)3312011 [last updated on April 1, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01327885 NLM identifier: NCT01327885
   Google Scholar
• NarayanSCarlsonEMChengHNovel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibilityBioorg Med Chem Lett2011211630163321324686
   PubMed Web of Science ®Google Scholar
• NarayanSCarlsonEMChengHNovel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivoBioorg Med Chem Lett2011211634163821324692
   PubMed Web of Science ®Google Scholar
• NarayanSCarlsonEMChengHNovel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor modelBioorg Med Chem Lett2011211639164321324687
   PubMed Web of Science ®Google Scholar